5 news items
Zymeworks Announces China NMPA Acceptance of Biologics License Application for Zanidatamab for Second-Line Treatment of Biliary Tract Cancer
ZYME
10 Jun 24
be removed surgically. About Zymeworks Inc. Zymeworks is a global biotechnology company committed to the discovery
Zymeworks To Report First Quarter 2024 Financial Results and Host Conference Call on May 2, 2024
ZYME
11 Apr 24
. About Zymeworks Inc. Zymeworks is a global biotechnology company committed to the discovery, development
Zymeworks Presents New Data from Multiple Preclinical Development Programs at 2024 American Association for Cancer Research Annual Meeting
ZYME
8 Apr 24
. Zymeworks is a global biotechnology company committed to the discovery, development, and commercialization of novel, multifunctional
Zymeworks Announces Appointment of Dr. Neil Gallagher to its Board of Directors
SNDX
ZYME
28 Mar 24
. Zymeworks is a global biotechnology company committed to the discovery, development, and commercialization of novel, multifunctional
Zymeworks Announces Participation in Upcoming Investor Conferences
ZYME
27 Mar 24
. Zymeworks is a global biotechnology company committed to the discovery, development, and commercialization of novel, multifunctional
- Prev
- 1
- Next